VELCADE,Rituximab,Cyclophosphamide and Decadron (VRCD)

Oncology Specialists, S.C.

Status and phase

Terminated

Phase 2

Conditions

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Treatments

Drug: VELCADE®

Drug: Decadron

Drug: Rituximab

Drug: Cyclophosphamide

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00413959

0606

Details and patient eligibility

About

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

Full description

This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab. Chemotherapy cycles will be given as outlined below every 35-days and will continue until two cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression, or a maximum of 8 cycles.

Enrollment

12 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Small Lymphocytic Lymphoma
Follicular Cell Lymphoma (grades I and II)
Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant
Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia
Marginal Zone Lymphoma
MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.
Adequate bone marrow function, renal function, and hepatic function as outlined in details below.
ECOG performance status of 0, 1, or 2
Able to read, understand, and sign an IRB approved informed consent